Tumors of the endocrine pancreas are extremely rare, and molecular mechanisms leading to their development are not well understood. A candidate tumor suppressor gene, DPC4, located at 18q21, has recently been shown to be inactivated in half of pancreatic adenocarcinoma xenografts. The close anatomical relationship of the exocrine and endocrine pancreas prompted us to determine the role of DPC4 in the tumorigenesis of 25 pancreatic islet cell tumors (11 insulinomas, nine nonfunctioning endocrine carcinomas, three gastrinomas, two vipomas). A mutation screening of the highly conserved COOH-terminal domain of DPC4 (exons 8 ± 11) was performed by single-strand conformational variant (SSCP) analysis and a PCR-based deletion assay. Five of nine (55%) non-functioning endocrine pancreatic carcinomas revealed either point mutations, small intragenic deletions or homozygous deletion of DPC4 sequences compared to none of the insulinomas, gastrinomas or vipomas. These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.
Introduction
Neuroendocrine pancreatic tumors (NPT) arise from the pancreatic islet cells and belong to the APUD (amine and precursor uptake and decarboxylation) system. These tumors are rare and account only for 1 ± 5% of pancreatic tumors. About 90% of NPTs are characterized by the extensive production of polypeptide hormones, whereas the remaining 10% are nonfunctioning neuronendocrine neoplasms (Edis et al., 1984) . The most common hormone producing NPTs are insulinomas and gastrinomas representing approximately 70 and 20% of NPTs, respectively. Vipomas, glucagonomas, somatostatinomas and others are extremely rare. Approximately 10 ± 20% of NPTs are associated with the multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant inherited tumor syndrome that predisposes to develop NPTs (Trump et al., 1996) .
Not least due to the rare occurrence of NPTs our knowledge of the genetic changes associated with the initiation and progression of these tumors is very limited, and available genetic data relies usually on small numbers of tumors analysed. A considerably high number of genetic alterations were found in the recently cloned MEN1 gene at chromosome 11q13 which is responsible for the MEN1 syndrome . Loss of heterozygosity including the region of the MEN1 gene was found in 93% of sporadic gastrinomas and in 50% of sporadic insulinomas. Somatic mutations of the MEN1 gene were identi®ed in 33% of sporadic gastrinomas and 17% of sporadic insulinomas . Ampli®cation of the HER-2/neu proto-oncogene was frequently observed in gastrinomas (Evers et al., 1994) . Furthermore, inactivation of the p16 INK4a tumor suppressor gene by either hypermethylation or homozygous deletion was identi®ed in more than 90% of gastrinomas and non-functioning neuroendocrine tumors (Muscarella et al., 1998) . Alterations of the K-ras oncogene and the p53 tumor suppressor gene, both frequently mutated in tumors of the exocrine pancreas, were not identi®ed in NPTs, and therefore are not likely to play an important role in NPT tumorigenesis (Yoshimoto et al., 1992; Yashiro et al., 1993) .
Recently, the putative tumor suppressor gene DPC4 (deleted in pancreatic carcinoma, locus 4) was identi®ed at human chromosome 18q21.1 (Hahn et al., 1996a) . DPC4 is a member of the highly conserved family of Smad proteins that are involved in the transduction of signals from the transforming growth factor û family of cytokines; DPC4 has subsequently been designated as Smad4 (Massague, 1996) . DPC4 was found to be inactivated, either by homozygous deletion or by point mutation together with a chromosomal deletion, in half of pancreatic adenocarcinomas (Hahn et al., 1996a, b) . This ®nding prompted us to investigate whether DPC4/Smad4 inactivation plays also a role in the tumorigenesis of NPTs.
Results
We screened the highly conserved COOH-terminal domain of the DPC4 gene for mutations in 25 microdissected NPTs (11 insulinomas, nine nonfunctioning neuroendocrine pancreatic carcinomas (NNPC), three gastrinomas and two vipomas). Exons 8 ± 11 were successfully ampli®ed in 24 tumors. Despite repeated attempts, DNA from the NNPC specimen 5955T which had a neoplastic cellularity of 90% failed to give rise to ampli®cation products of DPC4 exons 8 ± 11. In addition, multiplex PCR with primers speci®c for DPC4 exons 2 and 11 together with primers for Kras exon 1 failed to generate a speci®c DPC4 ampli®cation product whereas the speci®c K-ras PCR product was readily detectable (Figure 1 ). The quality of the tumor DNA was further assured by successful ampli®cation exons 4 and 5 of TP53, resulting in a slightly larger PCR product than expected for the DPC4 speci®c ampli®cation. We conclude from these experiments, that homozygous deletion of DPC4 is a likely explanation for the failure to generate a DPC4 speci®c PCR product in this tumor specimen.
SSCP analysis revealed a reproducible abnormal banding pattern in all ®ve control DNA samples derived from pancreatic xenografts which were known to harbor DPC4 mutations (Hahn et al., 1996a) . Upon SSCP analysis of the primary tumor samples using identical conditions reproducibly aberrant bands were seen in ®ve of 24 tumors, four of these being NNPCs (see examples in Figure 2 ). Sequence analysis of the aberrant SSCP products identi®ed point mutations or small intragenic deletions of the DPC4 sequence in all four NNPCs (Table 1) . Tumor 19377T carried an Asnto-Asp amino acid replacement at codon 369 in exon 8. The Asn369Asp mutation was not found in 50 normal control DNAs. The alteration was located within the highly conserved amino acid residues in the Smad homology region 2a (MH2a). Tumor 4176T revealed a missense mutation at codon 457 in exon 10, resulting in a nonconservative amino acid change from alanine to serine. Tumor 818T carried the nonsense mutation Arg-to-Stop at codon 515 in exon 11, a similar mutation has been described in a pancreatic cancer xenograft (Hahn et al., 1996a) . Tumor MB6T had a four basepair frameshift microdeletion at codon 528. All together, ®ve of nine (55%) NNPCs showed alterations of the DPC4 sequence. Examples of sequence alterations are given in Figure 3 . In tumors 4176T and 818T, the only mutation-positive tumors where constitutional normal DNA from the patient was available, the somatic nature of the mutation could Figure 1 Multiplex PCR of DPC4 (exons 2 and 11) and K-ras (exon 1) in NNPC specimens. NNPC 5955T shows no ampli®cation of exons 2 and 11 of DPC4 suggesting homozygous deletion. BXPC3, pancreatic cancer cell line with a known homozygous deletion of DPC4 as control; WT, wild-type Of all the other tumor types only the insulinoma 90aT revealed a band shift in exon 8. Sequencing of the variant band revealed a silent base change (TTT to TTC) at codon 362. This alteration was also found in the normal constitutional DNA and the tumor did not show LOH of 18q21 sequences. Therefore this alteration represents most likely a benign polymorphism.
From the 25 tumor specimens analysed, in 13 NPTs (two non-functioning neuroendocrine carcinomas, seven insulinomas, two vipomas, two gastrinomas) normal constitutional DNA was available to perform LOH analysis. Both NNPCs (specimens 4176T and 818T) and one case of insulinoma (specimen 101T) revealed LOH of 18q21 sequences.
Discussion
To our knowledge this is the ®rst report of DPC4/ Smad4 genetic alterations in pancreatic neuroendocrine tumors. Our data suggest that mutational inactivation of the DPC4 gene is a frequent event in NNPCs, whereas they do not play a signi®cant role in insulinomas, gastrinomas and vipomas. In addition, the one NNPC where we were unable to amplify DPC4 speci®c sequences is suggestive for homozygous deletion of the DPC4 gene region as a second mode of gene inactivation being also operative in this tumor type. Of note, it is likely that the DPC4 inactivation frequency is underestimated in our study for the following reasons: the mutation analysis was restricted to exons 8 ± 11 of DPC4, which together span the entire conserved COOH-terminal Smad homology region. However, because 90% of the DPC4 mutations reported thus far are located in the C-terminal region, the number of undetected mutations is expected to be low (Hahn et al., 1996a; Thiagalingam et al., 1996; Takagi et al., 1996; Nagatake et al., 1996; Hoque et al., 1997; Kim et al., 1996; Barrett et al., 1996; Lei et al., 1996; Kong et al., 1997; McGrogan et al., 1997; Howe et al., 1998) . The PCR-based detection of homozygous deletions, a mechanism of gene inactivation known to be important for the DPC4 gene (Hahn et al., 1996a; Schutte et al., 1996) , is complicated in primary tumor specimens by the presence of admixed nonneoplastic tissue. We attempted to minimize contamination from nonneoplastic tissue by microdissecting the tumor to enrich for the neoplastic cell fraction. Although we achieved by this approach a neoplastic cellularity of at least 80% in all tumor samples, the remaining nonneoplastic cell fraction (up to 20%) might have precluded a valid assessment of the homozygous deletion status for some of our cases. SSCP has been shown to be a highly sensitive method to identify mutations in PCR-generated fragments, nevertheless certain mutations may not be detected using this method. Furthermore, it is possible that some of the primary tumors in our collection had large intragenic deletions of DPC4, we would have missed, given the strategy for mutation detection used herein. Finally, loss of DPC4 function due to defects in transcriptional regulation, such as methylation of its promoter region would also have been missed upon analysis of genomic DNA.
To date a signi®cant number of DPC4 mutations has been found only in a few tumor types such as pancreatic adenocarcinoma xenografts (50%), colorectal carcinoma (17%) and biliary tract carcinomas (16%), whereas only a minority (57%) of cancers from other anatomic sides revealed DPC4 mutations (Hahn et al., 1996a; Schutte et al., 1996; Thiagalingam et al., 1996; Takagi et al., 1996; Nagatake et al., 1996; Kim et al., 1996; Barrett et al., 1996; Lei et al., 1996; Kong et al., 1997; Hoque et al., 1997; McGrogan et al., 1997; Hahn et al., 1998; Howe et al., 1998) . Our ®nding of DPC4 alterations in 55% of NNPCs suggest for this tumor type the highest DPC4 mutation rate reported in any primary tumor so far. Although more tumors of this type need to be analysed to ®rmly establish the mutation frequency in NNPCs, our data clearly support an important role of DPC4 in the carcinogenesis of NNPC. It remains speculative why NNPCs are a main target for DPC4 inactivation and none of the other neuroendocrine pancreatic tumor types. A possible explanation being that there is a basic biologic dierence between NNPCs and hormonesecreting NPTs. Their histologic similarities may mask a deeper distinction, such as their growth regulatory systems, which may be uncovered by detailed genetic analyses of the respective tumor types.
It is notable, that four of ®ve NNPC patients with DPC4 mutations had already liver metastases at the time of surgery and the remaining patient developed paraaortal lymph node metastases 25 months after initial surgery. In contrast, of the four mutationnegative NNPCs none had liver metastases and only one tumor had metastasized into the regional lymph nodes, while the majority of insulinomas and gastrinomas had a benign phenotype. Therefore, it is tempting to hypothesize that the occurrence of DPC4 alterations are important for this tumor type to develop a more aggressive phenotype re¯ected by an early occurrence of metastases.
Taken together, our data suggest inactivation of DPC4 is the second most common genetic event, besides alterations in the p16
INK4a tumor suppressor gene (Muscarella et al., 1998) , in NNPCs. Further- more, the frequency of DPC4 alteration may rival the frequency found in pancreatic adenocarcinomas and this should stimulate further research using this tumor type as a model system to investigate the tumor suppressive function of DPC4, helping to re®ne our picture of the role DPC4 signaling is playing in tumorigenesis.
Materials and methods

Tumor samples
Twenty-®ve NPTs (11 insulinomas, nine non-functioning neuroendocrine carcinomas, three gastrinomas and two vipomas) were obtained from the tissue bank of the Department of Surgery, Philipps-Universtiy of Marburg. Tissue specimens included 19 fresh-frozen and six paranembedded tumors. The diagnosis of neuroendocrine tumors was established by histological analysis, including a positive grimelius silver-staining and an immunopositive reaction for chromogranin A and gamma-enolase. The diagnosis of insulinoma required a fasting blood sugar of less than 45 mg/dl, hypoglycaemia symptoms, simultaneous elevated plasma insulin level of 45 microunits/ml and positive immunohistological diagnosis of insulinoma. The diagnosis of gastrinoma required an elevated fasting serum gastrin level, an increase in the serum gastrin level of 200 pg/ml after administration of i.v. secretin, and the characteristic immunohistological pattern for gastrinoma. A vipoma diagnosis was based on elevated fasting serum vasoactive intestinal polypeptide (VIP) levels and a strong immunoreaction of the tumor with VIP. Tumors were considered non-functional neuroendocrine tumors if patients clinically demonstrated no evidence of hormonally active tumors in the presence of a pancreatic mass with neuroendocrine characteristics by histopathological analysis. Twenty-four tumors were sporadic, one vipoma was obtained from a patient with a MEN1-syndrome.
Neoplastic cellularity of the tumors was independently assessed on hematoxylin and eosin stained slides by two pathologists (AR and PB). All tumor samples used for DNA isolation had a neoplastic cellularity of at least 80% after microdissection of the nonneoplastic tissue. Constitutional normal DNA derived, either from blood lymphocytes or from normal pancreatic tissue, was available from 13 patients. Genomic DNA from fresh-frozen tissue samples and blood was isolated using the QIAamp tissue and blood kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Genomic DNA from paran-embedded tissue was extracted by the salting-out method as described previously (Bartsch et al., 1995) .
PCR and SSCP
PCR ampli®cation was performed with 10 ± 20 ng of the isolated genomic DNA for 30 ± 35 cycles. The primers for SSCP analysis of exons 8 ± 11 that were designed to amplify a fragment length of 250 bp or less have previously been described (Hahn et al., 1998) . The PCR products were electrophoresed through 0.56 MDE gels (Mutation Detection Enhancement, Serogel, Biozym) with and without 5% glycerol at room temperature for 12 h at 6 W as described previously (Bartsch et al., 1995) . The resulting products were visualized by autoradiography. The presence of abnormally migrating DNA bands was con®rmed in several independent PCR reactions loaded on dierent gels. Genomic DNA of pancreatic cancer xenografts PX23, PX74, PX28, PX86 and PX102 (kindly provided by Dr S Kern, Department of Oncology and Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA), which were known to harbor DPC4 mutations (Hahn et al., 1996a) , were used as controls for the sensitivity of mutation detection under these SSCP conditions.
Sequence analysis
Aberrant bands were cut from the gel, eluted, and reampli®ed by PCR using the original PCR primers. The resulting products were either directly sequenced by cycle sequencing (SequiTherm, Epicentre) or, in cases where it proved dicult to isolate the aberrant band without contamination from the nearby normal band, the PCR product was ®rst ligated into the pCRII TA-cloning vector (Invitrogen) and then eight to ten independent clones were sequenced (SequiTherm, Epicentre). To distinguish PCR errors from tumor-speci®c alterations, mutations were only scored when at least half of the clones showed the sequence alteration.
Loss of heterozygosity analysis
Microsatellite markers D18S363, D18S877, D18S474, D18535 and D18S46 from the DPC4-region have been used to analyse loss of heterozygosity (Hahn et al., 1996b) . PCR ampli®cation and PCR product analysis were performed as described (Hahn et al., 1995) . Loss of heterozygosity (LOH) was de®ned as a 450% reduction in intensity by visual inspection in either of the two alleles as compared to those in constitutional normal DNA.
Deletion analysis
Tumor samples were evaluated for homozygous deletion of exons 2 and 11 of DPC4 by multiplex PCR. Exon 1 of the K-ras oncogene was coampli®ed as an internal control to assure the integrity of the DNAs. The forward primer sequence for K-ras exon 1 was 5'GGCCTGCTGAAAAT-GACTGA3', and the reverse was 5'TTGTTGGATCA-TATTCGTCC3'. Multiplex PCR was performed with 10 ± 20 ng of genomic DNA for 35 cycles. The products were resolved on 10% nondenaturing polyacrylamide gels, stained with ethidium bromide and visualized by UVtransillumination.
